LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.45 -3.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.41

Max

1.51

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+168.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	137M 631M
Eelmine avamishind	4.78
Eelmine sulgemishind	1.45

Uudiste sentiment

By Acuity

50%

167 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2026, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25. veebr 2026, 23:15 UTC

Tulu

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25. veebr 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25. veebr 2026, 23:47 UTC

Tulu

Ferrovial 4Q Net EUR197M >FER.MC

25. veebr 2026, 23:45 UTC

Tulu

Ferrovial 4Q Rev EUR2.72B >FER.MC

25. veebr 2026, 23:42 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25. veebr 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Company's Business Operations Remain Normal >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY EPS CNY47.67 >TCOM

25. veebr 2026, 23:06 UTC

Tulu

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25. veebr 2026, 23:01 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25. veebr 2026, 23:00 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

25. veebr 2026, 23:00 UTC

Market Talk

Tulu

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25. veebr 2026, 22:56 UTC

Market Talk

Tulu

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25. veebr 2026, 22:43 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25. veebr 2026, 22:40 UTC

Market Talk

Tulu

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25. veebr 2026, 22:40 UTC

Tulu

Karoon Energy Says Search for New CFO Well Advanced

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says CFO Ray Church to Leave Company

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25. veebr 2026, 22:38 UTC

Tulu

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

168.67% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 168.67%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

167 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.